NEJM: Crizotinib Effective in Phase 1 Trial Against ROS1 Lung Cancer
September 30, 2014 · No comments
The New England Journal of Medicine reports positive results of a phase 1 clinical trial of the drug crizotinib against the subset of lung cancer marked by rearrangement of the gene ROS1.
Bevacizumab (Avastin) slows the growth of new blood vessels that tumors need to supply themselves with nutrients. Will it work better in combination with the new immunotherapy drug MPDL3280A?
Collaboration Between CU Cancer Center and NantBioScience Targets Ral Protein
September 16, 2014 · Comments Off
Collaboration between CU Cancer Center and NantBioScience will allow Theodorescu and team to work toward drugs that target Ral protein activation, implicated in nearly a third of all cancers.
New Knowledge of Genes Driving Bladder Cancer Points to Targeted Treatments
September 15, 2014 · Comments Off
A collaborative study between researchers at the University of Colorado Cancer Center and the National Cancer Institute (NCI) published today in the journal Clinical Cancer Research takes an important step toward defining the genetics of bladder cancer, and implies there may be at least two distinct genetic types of the disease.
Pierce Brosnan Announces New Stand Up To Cancer Dream Team Dedicated to Ovarian Cancer
September 9, 2014 · Comments Off
Stand Up To Cancer, Pierce Brosnan and Colorado's HERA Women's Cancer Foundation announce new Dream Team to fight ovarian cancer.
Allen Lichter, CEO of ASCO, Says Big Data, Cost/Value and “-Omics” Will Dominate Oncology in 2030
September 4, 2014 · Comments Off
At the CU Cancer Center Fall Retreat 2014, Allen S. Lichter, MD, FASCO, CEO of ASCO, points the way toward the future of oncology in 2030
University of Colorado’s Online Screening for Rare Lung Cancer Subtypes Opens Door to New Kind of Clinical Trial
August 21, 2014 · Comments Off
CU Cancer Center clinical trial tests the drug ponatinib against lung cancer with mutation in the gene FGFR1. Online questionnaire and free lung cancer tissue testing at CU determines eligibility.
National Clinical Trial Tests Power of COXEN Model to Predict Best Treatment for Bladder Cancer
August 13, 2014 · Comments Off
COXEN, a computer model that suggests treatment based on cancer genetics, is being tested in a new clinical trial, here at the CU Cancer Center and nationally via clinical sites of the Southwest Oncology Research Group.
“Treatments Waiting to be Discovered” Inside New Database
August 5, 2014 · Comments Off
University of Colorado Cancer Center database, multiMiR, allows researchers to search microRNA, gene, disease, and drug interactions.
NTRK1: a new oncogene and target in lung cancer
August 5, 2014
Does Study of Down Syndrome Hold a Possible Cancer Cure?
October 20, 2014 · No comments
CU Cancer Center director elected to Institute of Medicine
October 20, 2014 · No comments
ALK amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer grants cancer research colorado cancer stem cells Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant james degregori jennifer richer leukemia lung cancer lung cancer research melanoma microRNA ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
CU Cancer Center director elected to Institute of Medicine - Colorado Cancer Blogs fb.me/1n5capTT5
Joaquin Espinosa, PhD, writing for the Huffington Post, wonders if it is cancer-protecting genes on chromosome... fb.me/79fAjNF0D